Publications

• Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD),
  July 2, 2007.
  Taylor PA, Ehrhardt MJ, Lees CJ, Tolar J, Weigel BJ, Panoskaltsis-Mortari A, Serody JS, Brinkmann V, Blazar BR.
  
  
  
• Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients,
  February 1, 2007.
  Taylor PA, Ehrhardt MJ, Roforth MM, Swedin JM, Panoskaltsis-Mortari A, Serody JS, Blazar BR.
  
  
  
• Diagnosis and treatment of chronic graft-versus-host disease.
  January, 2006
  Gilman AL, Serody J.
  
  
  
• Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies.
  December, 2005.
  Gabriel DA, Shea TC, Serody JS, Moore DT, Kirby SL, Harvey D, Krasnov C.
  
  
  
• A novel viral system for generating antigen-specific T cells.
  September 1, 2005
  Moran TP, Collier M, McKinnon KP, Davis NL, Johnston RE, Serody JS.
  
  
  
• Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease.
  November 1,2005.
  Wysocki CA, Jiang Q, Panoskaltsis-Mortari A, Taylor PA, McKinnon KP, Su L, Blazar BR, Serody JS.
  
  
  
• C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis.
  April 15,2005
  van Deventer HW, O'Connor W, Brickey WJ, Aris RM, Ting JP, Serody JS.
  
  
  
• Leukocyte migration and graft-versus-host disease.
  June 1, 2005
  Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS.
  
  
  
• Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).
  April 15, 2005.
  Taylor PA, Panoskaltsis-Mortari A, Freeman GJ, Sharpe AH, Noelle RJ, Rudensky AY, Mak TW, Serody JS, Blazar BR.
  
  
  
• Donor T-cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation.
  March 15, 2005
  Hildebrandt GC, Olkiewicz KM, Choi S, Corrion LA, Clouthier SG, Liu C, Serody JS, Cooke KR.
  
  
  
• CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease.
  September 1, 2004.
  Blazar BR, Levy RB, Mak TW, Panoskaltsis-Mortari A, Muta H, Jones M, Roskos M, Serody JS, Yagita H, Podack ER, Taylor PA.
  
  
  
• L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection.
  December 1,2004.
  Taylor PA, Panoskaltsis-Mortari A, Swedin JM, Lucas PJ, Gress RE, Levine BL, June CH, Serody JS, Blazar BR.
  
  
  
• Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning.
  July 15, 2004.
  Wysocki CA, Burkett SB, Panoskaltsis-Mortari A, Kirby SL, Luster AD, McKinnon K, Blazar BR, Serody JS.
  
  
  
• Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer.
  September, 2004.
  Dees EC, McKinnon KP, Kuhns JJ, Chwastiak KA, Sparks S, Myers M, Collins EJ, Frelinger JA, Van Deventer H, Collichio F, Carey LA, Brecher ME, Graham M, Earp HS, Serody JS.
  
  
  
• A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells.
  June 1, 2004.
  Sauer MG, Ericson ME, Weigel BJ, Herron MJ, Panoskaltsis-Mortari A, Kren BT, Levine BL, Serody JS, June CH, Taylor PA, Blazar BR.
  
  
  
• 
  June 15, 2004>
  Lindley C, Shea T, McCune J, Shord S, Decker J, Harvey D, Petros WP, Garbriel D, Serody J, Kirby S, Wiley J.
  
  
  
• Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.
  May 25, 2004
  Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I, Riordan W, Sitcheran R, Wysocki C, Serody JS, Blazar BR, Sayers TJ, Murphy WJ.
  
  
  
• The effect of oral mucositis on morbidity and mortality in bone marrow transplant.
  December 30, 2003.
  Gabriel DA, Shea T, Olajida O, Serody JS, Comeau T.
  
  
  
• In vivo imaging of graft-versus-host-disease in mice.
  May 1, 2004.
  Panoskaltsis-Mortari A, Price A, Hermanson JR, Taras E, Lees C, Serody JS, Blazar BR.
  
  
  
• An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignancies.
  July 9, 2003.
  Shea TC, Bruner R, Wiley JM, Serody JS, Sailer S, Gabriel DA, Capel E, Moore DT, Dent G, Bentley S, Brecher ME.